TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01303224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, low dose, once daily, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, intermediate dose, once daily, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, high dose, once daily, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
Study: NCT03283605

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
Study: NCT01139437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose HPIV2 Vaccine
Description: 10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose HPIV2 Vaccine
Description: 10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
Study: NCT04075812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Stimulator
Study: NCT01139437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose HPIV2 vaccine
Description: 10\^5 TCID50 administered in a single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT01689792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CitraFleet
Study: NCT00291057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG
Description: 30 minute application
Study: NCT00868010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: 5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
Study: NCT00907413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP and Photodynamic Therapy
Description: Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
Study: NCT03165604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard information
Description: The participates will be given a standard information regarding the water drink before physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard information
Description: The participates will be given a standard information regarding the water drink before physical activity
Study: NCT00907413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP only
Description: Endoscopic retrograde cholangiopancreatography and stenting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP only
Description: Endoscopic retrograde cholangiopancreatography and stenting.
Study: NCT01085825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D & C abortion
Description: Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D & C abortion
Description: Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
Study: NCT00830401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of predefined abnormality by hysteroscopic surgery
Description: * Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacinum/Doxycycline
Description: Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
Study: NCT02612337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study: NCT00099047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03165604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive information
Description: The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive information
Description: The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity
Study: NCT02146495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous EEG and fMRI recordings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial
Description: Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial
Description: Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.
Study: NCT01947413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
Study: NCT02613000

Intervention type: OTHER
Intervention: No intervention
Study: NCT01947413

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham theta burst stimulation
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
Study: NCT03181113

Intervention type: DRUG
Intervention: Peginterferon Alfa-2A
Description: pre-received standard peginterferon alfa-2a therapy
Study: NCT01975688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD.
Study: NCT02998957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuTENS
Description: Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AcuTENS
Description: Portable TENS electrostimulation device with no electrical output
Study: NCT03670030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
Study: NCT01285349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple HIV/STI prevention intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual HIV/STI prevention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Couple Wellness Promotion
Study: NCT02678429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change DBS programming
Description: Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Change DBS programming
Description: Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
Study: NCT00545870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal application
Study: NCT03225859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Program
Description: This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
Study: NCT01685398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01671579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bowel ultrasound
Description: The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance enterography (MRE)
Description: The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
Study: NCT03310060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel
Description: Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
Study: NCT00049387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo partial brain radiation therapy
Study: NCT00038389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vioxx
Description: Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
Study: NCT01794338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice Arm
Description: Biologic mesh to be placed during hernia repair surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-A Arm
Description: Bioabsorbable mesh to be placed during hernia repair surgery
Study: NCT00336856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
Study: NCT03140059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated application of aPDT
Description: Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
Study: NCT02043899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [124I]meta-Iodobenzylguanidine
Description: Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
Study: NCT03940768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Description: Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus plantarum 299v
Description: Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administration of placebo in cancer patients who receive home enteral nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo in cancer patients who receive home enteral nutrition.
Study: NCT03817047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical education
Description: Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical education
Description: Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical active learning
Description: The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be happy
Description: The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
Study: NCT02522624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Description: Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
Study: NCT00749710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: ORIF - surgical treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no antiaggregant therapy
Description: ORIF - surgical treatment
Study: NCT03196609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of stool and serum samples
Description: During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)
Study: NCT04643145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscopy for renal calculi less than 20 mm
Description: Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscopy for renal calculi less than 20 mm
Description: Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
Study: NCT00458224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental counseling
Description: Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
Study: NCT00854100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + placebo
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study: NCT00798759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
Study: NCT04273880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10mg of MPH taken an hour and a half before one of the testing sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: 90 mg of Vitamin C taken an hour and a half before the other testing session
Study: NCT00947440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-072
Description: See arm description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-072
Description: See arm description for more information
Study: NCT03320824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Dermal Filler
Description: hyaluronic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: FDA Approved Dermal Filler
Description: hyaluronic acid